Publication

A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland

Journal Paper/Review - Jan 16, 2020

Panje Cédric, Schwenkglenks M, Gautschi O, Plasswilm Ludwig, Aebersold D M, Dedes K J, Lorez M, Pardo E, Barbier M, Lupatsch J E, Swiss Group for Clinical Cancer Research (SAKK)